Endocyte, Inc. announced that Scot L. Harper, Ph.D., has been appointed as vice president of clinical operations. Dr. Harper will be responsible for all operational aspects of advancing Endocyte's clinical pipeline, including continued enrollment in the Phase 3 PROCEED and Phase 2b TARGET trials for vintafolide and etarfolatide, and the three new drug candidates scheduled to enter the clinic before the end of 2014. Harper brings more than twenty-five years of clinical operations experience to his position at Endocyte. He joins the company from PAREXEL International, where he was the global portfolio director for oncology, overseeing clinical activities for oncology drugs ranging from Phase 1 to Phase 4 of development. Prior to this position, he was the vice president of Novartis' North American clinical operations, where he managed clinical operations of all stages of development, including products such as Gleevec, Tasigna and Diovan.

Endocyte, Inc. reported unaudited earnings results for the first quarter ended March 31, 2013. For the period, the company's collaboration revenue was $14,514,000. Loss from operations was $4,001,000 against $9,511,000 a year ago. Net loss was $3,862,000 or $0.11 basic and diluted per share against $9,770,000 or $0.27 basic and diluted per share a year ago. The company confirms prior guidance, expecting that its cash, cash equivalents and investments will be between $145.0 - $160.0 million at December 31, 2013.

Endocyte, Inc., Q1 2013 Earnings Call, May 02, 2013